Notably, emerging molecular markers like CDKN2A/B homozygous deletion are linked to poorer prognosis in IDH-mutant gliomas, refining risk assessment and guiding decisions, such as the use of vorasidenib (16). This evidence concerns the gene IDH2 and glioma.